Cart
sales@molnova.com
Tesidolumab
CAS No. 1531594-08-7
Tesidolumab( —— )
Catalog No. M36737 CAS No. 1531594-08-7
Tesidolumab (LFG316) is a fully human IgG1/λ anti-C5 monoclonal antibody.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 301 | Get Quote |
|
| 5MG | 471 | Get Quote |
|
| 10MG | 787 | Get Quote |
|
| 25MG | 1132 | Get Quote |
|
| 50MG | 1518 | Get Quote |
|
| 100MG | 2007 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameTesidolumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionTesidolumab (LFG316) is a fully human IgG1/λ anti-C5 monoclonal antibody.
-
DescriptionTesidolumab (LFG316) is a fully-human IgG1/λ anti-C5 monoclonal antibody of 143 kDa (without glycosylation). Tesidolumab (LFG316) blocks cleavage of C5 and prevents subsequent formation of the membrane attack complex.
-
In VitroTesidolumab (LFG316) possesses a half-life in humans of approximately 9 days.Tesidolumab (LFG316) binds to a distinct epitope to that of eculizumab and ravulizumab, distant to Arg 885.
-
In Vivo——
-
Synonyms——
-
PathwayImmunology/Inflammation
-
TargetComplement System
-
RecptorComplement System
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1531594-08-7
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Jun-Ichi Nishimura, et al. Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria. Haematologica. 2022 Jun 1;107(6):1483-1488.?
molnova catalog
related products
-
LNP023
LNP023 (LNP-023) is a highly potent, reversible, selective inhibitor of factor B (IC50=10 nM).
-
Compstatin control p...
Compstatin control peptide acetate is an inhibitor of complement protein C3 by binding and inhibiting the cleavage of complement C3.
-
BR111
BR111 is a potent, highly selective and orally active antagonist of complement C3a receptor (C3aR) with IC50 of 85?±?40 ?nM.
